All In Biotech

Drug Trial Radar · NCT06169722

TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))

TDI01 for Treatment of Moderate or Severe Chronic Graft-Versus-Host Disease After Failure of at Least 1 and Not More Than 5 Lines of Systemic Therapy: an Open Label, Multi-center, ph1/2 Study

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Feb 6, 2024

Primary completion

Feb 2026

Study completion Aug 2027

Sponsor

Sponsor type
Industry
First posted
Dec 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. Phase Ib study stage: Primary objective: To evaluate the efficacy and safety Secondary objectives: To evaluate the population pharmacokinetic characteristics 2. Phase II study stage: Primary objective: To evaluate the efficacy Secondary objectives: To evaluate the safety

Conditions

  • GVHD, Chronic

Interventions

  • TDI01 suspensionDrug

    200mg or 400mg oral once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib study stage:The best overall response rate (BORR)Time frame: 24 weeks.
  2. Phase Ib study stage:adverse eventsTime frame: 24 weeks.
  3. Phase II study stage:The best overall response rate (BORR)Time frame: 24 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.